Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $106.00 target price on the stock.

MNPR has been the subject of several other reports. HC Wainwright started coverage on Monopar Therapeutics in a research report on Tuesday, August 26th. They set a “buy” rating and a $70.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $74.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, August 27th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, September 16th. Oppenheimer started coverage on Monopar Therapeutics in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $77.00 price objective for the company. Finally, Raymond James Financial started coverage on Monopar Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $80.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Monopar Therapeutics currently has an average rating of “Buy” and an average target price of $82.33.

Monopar Therapeutics Price Performance

MNPR opened at $77.44 on Tuesday. Monopar Therapeutics has a 12 month low of $4.50 and a 12 month high of $79.80. The stock has a market capitalization of $477.80 million, a price-to-earnings ratio of -23.26 and a beta of 1.20. The business has a fifty day moving average price of $43.86 and a 200 day moving average price of $39.04.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.12. On average, research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Activity

In other news, Director Christopher M. Starr sold 16,800 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company’s stock, valued at approximately $206,920. The trade was a 76.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Chandler Robinson sold 16,800 shares of the business’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares of the company’s stock, valued at $2,938,880. The trade was a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 42,504 shares of company stock valued at $1,700,160. Insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $34,000. AlphaQuest LLC purchased a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $44,000. JPMorgan Chase & Co. raised its stake in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund purchased a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $104,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.